Brief: Brickell Biotech Announces Initiation Of A Phase 1 Study Of Sofpironium Bromide Gel In Primary Palmoplantar Hyperhidrosis Patients By Its Development Partner, Kaken Pharmaceutical In Japan
24/06/2021 13:07
June 24 (Reuters) - Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH ANNOUNCES INITIATION OF A PHASE 1 STUDY
OF
SOFPIRONIUM BROMIDE GEL IN PRIMARY PALMOPLANTAR HYPERHIDROSIS
PATIENTS BY ITS DEVELOPMENT PARTNER, KAKEN PHARMACEUTICAL IN
JAPAN
* BRICKELL BIOTECH - EXPECTS TO REPORT TOPLINE RESULTS FROM
CARDIGAN I AND II PIVOTAL STUDIES IN Q4 OF 2021
Source text for Eikon: ID:nGNXbXjHgQ
Further company coverage: BBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx